Aldeyra Therapeutics Inc (ALDX) Sees Large Volume Increase

aldeyra-therapeutics-inc-aldx-sees-large-volume-increase.jpg

Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares saw an uptick in trading volume on Thursday . 51,895 shares traded hands during mid-day trading, an increase of 19% from the previous session’s volume of 43,782 shares.The stock last traded at $6.24 and had previously closed at $5.95.
Separately, Stifel Nicolaus began coverage on Aldeyra Therapeutics in a report on Friday, July 1st. They issued a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aldeyra Therapeutics presently has an average rating of “Buy” and an average price target of $13.15.
The firm has a 50-day moving average of $5.73 and a 200 day moving average of $5.50. The firm’s market capitalization is $38.16 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/aldeyra-therapeutics-inc-aldx-sees-large-volume-increase.html

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.03. Equities research analysts anticipate that Aldeyra Therapeutics Inc will post ($1.69) EPS for the current fiscal year.
Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock valued at $712,000 after buying an additional 3,718 shares during the period. BlackRock Fund Advisors raised its stake in shares of Aldeyra Therapeutics by 1,944.6% in the second quarter. BlackRock Fund Advisors now owns 20,630 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 19,621 shares during the period. Boxer Capital LLC raised its stake in shares of Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock valued at $1,657,000 after buying an additional 228,084 shares during the period. FMR LLC raised its stake in shares of Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock valued at $10,230,000 after buying an additional 360,000 shares during the period. Finally, Perceptive Advisors LLC raised its stake in shares of Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock valued at $11,041,000 after buying an additional 700,000 shares during the period.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Aldeyra Therapeutics Inc (ALDX) Sees Large Volume Increase"

Leave a comment

Your email address will not be published.

*